Scientists Draw Sharp Line Between Kratom Leaf and Synthetic 7-OH: 'Danger Profile Becomes Greater and Greater'

Why it matters

As the DEA moves to schedule concentrated 7-OH and public debate heats up, leading scientists are drawing a clear, evidence-based distinction between the natural kratom plant and synthetic kratom derivatives — a nuance that regulators, clinicians, and consumers urgently need.

The big picture

Spectrum News is running a four-part investigative series titled "Kratom: From Leaf to Lab." Part 2 focuses on the chemistry and comparative danger of 7-OH versus whole-leaf kratom. The series draws on interviews with Dr. Christopher McCurdy of the University of Florida, identified as the world's leading kratom pharmacologist, and Bryan Denham of Clemson University who has published multiple kratom studies. The distinction between natural mitragynine and concentrated 7-OH has become the central technical question in the current federal scheduling debate.

Key findings

• 7-OH is a metabolite of mitragynine, not an alkaloid; it forms as the kratom leaf oxidizes after harvest — it is not the same as the plant itself
• Dr. Christopher McCurdy describes 7-OH as "not as potent as heroin and fentanyl, but more potent than morphine"
• Whole-leaf kratom is described by McCurdy as "very different from a traditional opioid product like fentanyl, heroin, or morphine"
• Some 7-OH products are sold with no age restrictions in certain states, shaped like ice cream cones or brightly colored gummies
• As products evolve from leaf to extracts to synthetics, McCurdy states: "the danger profile becomes greater and greater and greater"

What they say

"The leaf material, the powdered leaf material, I would say is very different from a traditional opioid product like fentanyl, heroin or morphine. Let me be clear: I think it can be dangerous on its own." — Dr. Christopher McCurdy, University of Florida, world-leading kratom researcher

Bottom line

The nation's top kratom scientists are unanimous: concentrated 7-OH and the plant itself are distinct substances with meaningfully different risk profiles — a distinction the federal scheduling action is now attempting to codify into law.